204 related articles for article (PubMed ID: 21958851)
21. 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Imani F; Agopian VG; Auerbach MS; Walter MA; Imani F; Benz MR; Dumont RA; Lai CK; Czernin JG; Yeh MW
J Nucl Med; 2009 Apr; 50(4):513-9. PubMed ID: 19289420
[TBL] [Abstract][Full Text] [Related]
22. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
[TBL] [Abstract][Full Text] [Related]
23. 18F-DOPA PET/CT in the evaluation of hereditary SDH-deficiency paraganglioma-pheochromocytoma syndromes.
Marzola MC; Chondrogiannis S; Grassetto G; Rampin L; Maffione AM; Ferretti A; Opocher G; Schiavi F; Colletti PM; Rubello D
Clin Nucl Med; 2014 Jan; 39(1):e53-8. PubMed ID: 23856824
[TBL] [Abstract][Full Text] [Related]
24. I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report.
Grassi I; Nanni C; Vicennati V; Castellucci P; Allegri V; Montini GC; Pagotto U; di Dalmazi G; Pasquali R; Fanti S
Clin Nucl Med; 2011 Feb; 36(2):124-6. PubMed ID: 21220975
[TBL] [Abstract][Full Text] [Related]
25. Vesicular monoamine transporter protein expression correlates with clinical features, tumor biology, and MIBG avidity in neuroblastoma: a report from the Children's Oncology Group.
Temple W; Mendelsohn L; Kim GE; Nekritz E; Gustafson WC; Lin L; Giacomini K; Naranjo A; Van Ryn C; Yanik GA; Kreissman SG; Hogarty M; Matthay KK; DuBois SG
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):474-481. PubMed ID: 26338179
[TBL] [Abstract][Full Text] [Related]
26. Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.
Hoegerle S; Nitzsche E; Altehoefer C; Ghanem N; Manz T; Brink I; Reincke M; Moser E; Neumann HP
Radiology; 2002 Feb; 222(2):507-12. PubMed ID: 11818620
[TBL] [Abstract][Full Text] [Related]
27. A "pheo" lurks: novel approaches for locating occult pheochromocytoma.
Pacak K; Goldstein DS; Doppman JL; Shulkin BL; Udelsman R; Eisenhofer G
J Clin Endocrinol Metab; 2001 Aug; 86(8):3641-6. PubMed ID: 11502790
[TBL] [Abstract][Full Text] [Related]
28. Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome.
Pacak K; Eisenhofer G; Ilias I
Hormones (Athens); 2009; 8(2):111-6. PubMed ID: 19570738
[TBL] [Abstract][Full Text] [Related]
29. Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model.
Gaertner FC; Wiedemann T; Yousefi BH; Lee M; Repokis I; Higuchi T; Nekolla SG; Yu M; Robinson S; Schwaiger M; Pellegata NS
J Nucl Med; 2013 Dec; 54(12):2111-7. PubMed ID: 24136933
[TBL] [Abstract][Full Text] [Related]
30. [Contemporary nuclear medicine diagnostics of neuroendocrine tumors].
Srp Arh Celok Lek; 2015; 143(1-2):108-15. PubMed ID: 25845263
[TBL] [Abstract][Full Text] [Related]
31. 6-[18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma.
Pacak K; Eisenhofer G; Carrasquillo JA; Chen CC; Li ST; Goldstein DS
Hypertension; 2001 Jul; 38(1):6-8. PubMed ID: 11463751
[TBL] [Abstract][Full Text] [Related]
32. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
33. The role of 18F-FDOPA and 18F-FDG-PET in the management of malignant and multifocal phaeochromocytomas.
Taïeb D; Tessonnier L; Sebag F; Niccoli-Sire P; Morange I; Colavolpe C; De Micco C; Barlier A; Palazzo FF; Henry JF; Mundler O
Clin Endocrinol (Oxf); 2008 Oct; 69(4):580-6. PubMed ID: 18394015
[TBL] [Abstract][Full Text] [Related]
34. Comparison of (68)Ga-DOTA-Tyr(3)-octreotide and (18)F-fluoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients.
Putzer D; Gabriel M; Kendler D; Henninger B; Knoflach M; Kroiss A; Vonguggenberg E; Warwitz B; Virgolini IJ
Q J Nucl Med Mol Imaging; 2010 Feb; 54(1):68-75. PubMed ID: 20168288
[TBL] [Abstract][Full Text] [Related]
35. Adrenal tracer uptake by
Noordzij W; Glaudemans AWJM; Schaafsma M; van der Horst-Schrivers ANA; Slart RHJA; van Beek AP; Kerstens MN
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1560-1566. PubMed ID: 31011769
[TBL] [Abstract][Full Text] [Related]
36. False-positive findings on 6-[18F]fluor-l-3,4-dihydroxyphenylalanine PET (
Berends AMA; Kerstens MN; Bolt JW; Links TP; Korpershoek E; de Krijger RR; Walenkamp AME; Noordzij W; van Etten B; Kats-Ugurlu G; Brouwers AH; van der Horst-Schrivers ANA
Eur J Endocrinol; 2018 Aug; 179(2):125-133. PubMed ID: 29875288
[TBL] [Abstract][Full Text] [Related]
37. Comparison of the amino acid tracers 18F-FET and 18F-DOPA in high-grade glioma patients.
Lapa C; Linsenmann T; Monoranu CM; Samnick S; Buck AK; Bluemel C; Czernin J; Kessler AF; Homola GA; Ernestus RI; Löhr M; Herrmann K
J Nucl Med; 2014 Oct; 55(10):1611-6. PubMed ID: 25125481
[TBL] [Abstract][Full Text] [Related]
38.
Feral CC; Tissot FS; Tosello L; Fakhry N; Sebag F; Pacak K; Taïeb D
Eur J Nucl Med Mol Imaging; 2017 May; 44(5):812-821. PubMed ID: 27900521
[TBL] [Abstract][Full Text] [Related]
39. Noninvasive monitoring of a murine model of metastatic pheochromocytoma: a comparison of contrast-enhanced microCT and nonenhanced MRI.
Martiniova L; Kotys MS; Thomasson D; Schimel D; Lai EW; Bernardo M; Merino MJ; Powers JF; Ruzicka J; Kvetnansky R; Choyke PL; Pacak K
J Magn Reson Imaging; 2009 Mar; 29(3):685-91. PubMed ID: 19243052
[TBL] [Abstract][Full Text] [Related]
40. F-18-Dopa Positron Emission Tomography/Computed Tomography Is More Sensitive Than Whole-Body Magnetic Resonance Imaging for the Localization of Persistent/Recurrent Disease of Medullary Thyroid Cancer Patients.
Terroir M; Caramella C; Borget I; Bidault S; Dromain C; El Farsaoui K; Deandreis D; Grimaldi S; Lumbroso J; Berdelou A; Hadoux J; Hescot S; Hartl D; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2019 Oct; 29(10):1457-1464. PubMed ID: 31530235
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
